OR-LATTICE-SEMICONDUCTOR
5.12.2023 18:21:34 CET | Business Wire | Press release
Today at the Lattice Developers Conference, Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, continued its rapid product portfolio expansion with the launch of multiple new hardware and software solutions. Lattice introduced two new innovative mid-range FPGA device families built on the award-winning mid-range Lattice Avant™ platform – Lattice Avant™-G and Lattice Avant™-X, designed for general purpose and advanced connectivity, respectively. Lattice announced new versions of its application-specific solution stacks for artificial intelligence (AI), embedded vision, security, and factory automation, each of which are expanded with new features and capabilities to help accelerate customer time-to-market. Lattice released updated versions of its software tools and Glance by Mirametrix® computer vision software.
“At Lattice, we’re focused on enabling our customers to accelerate their designs with new levels of power efficiency and performance through our rapidly growing hardware and software portfolio,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “We’re excited to expand on the strong customer and developer momentum we’ve established for Lattice Avant, enabling the next era of innovation.”
Innovative Mid-range FPGAs
Built on the award-winning Lattice Avant platform, the Avant-G and Avant-X FPGA families offer power efficiency, advanced connectivity, and optimized compute for mid-range applications across the Communications, Computing, Industrial, and Automotive markets.
Lattice Avant™-G FPGA Family
Avant-G general purpose FPGAs are designed to enable a wide range customer needs by offering seamless, flexible interface bridging and optimized compute for system expandability. Lattice Avant-G devices offer best-in-class signal processing and AI, flexible I/O supporting a range of system interfaces, while providing dedicated LPDDR4 memory interfaces at 2400 Mbps.
Lattice Avant™-X FPGA Family
Avant-X advanced connectivity FPGAs are designed to enable high bandwidth and security, with a feature set tailored to customer needs for signal aggregation and high throughput. Lattice Avant-X devices offer up to 1 Terabit per second total system bandwidth, PCIe® Gen 4 controllers with hard DMA, and a security engine to encrypt user data in motion providing quantum safe cryptography.
Lattice Avant-G and Avant-X FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.
Expanded Solution Stacks
Lattice’s solution stacks are designed to speed customer development and time-to-market by giving them a toolkit of hardware, software, and IP tailored to the needs of their application. Lattice today announced four solution stack updates in AI with Lattice sensAI™, embedded vision with Lattice mVision™, security with Lattice Sentry™, and factory automation with Lattice Automate™. These updates include improved performance with upgraded an accelerator engine, expanded IP and reference designs, added security features, and enablement of more industry standards.
Enhanced Software Capabilities
Lattice is committed to providing best-in-class, easy-to-use software tools that help enhance customers’ design experience and design environment. Key updates to Lattice Propel™ and Lattice Radiant™ software includes adding full support for the new Lattice Avant-G and Avant-X FPGA families, the introduction of enhanced ease-of-use and scripting to Radiant, and expanding the IP portfolio in Propel.
Advanced computer vision software Glance by Mirametrix® was also updated with new features to expand its applicability across Edge applications for various markets. Updates include a new smart avatar privacy feature and 3D head pose for low power capability.
These product announcements were made today during the livecast at the Lattice Developers Conference, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 5-7, 2023, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.
For more information on the new products, please read the latest blog and visit:
- Lattice Avant-G FPGAs
- Lattice Avant-X FPGAs
- Lattice sensAI solution stack
- Lattice mVision solution stack
- Lattice Sentry solution stack
- Lattice Automate solution stack
- Lattice Propel
- Lattice Radiant
- Glance by Mirametrix
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, or Weibo.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205062926/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
